DIABETES MELLITUS IS A CHRONIC DISEASE that is growing in prevalence worldwide.
Pharmacologic therapy is often necessary to achieve optimal glycemic control in the …

Purpose Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the newest class of
antihyperglycemic agents available on the market. Regulator warnings and concerns regarding the …

Lowering of low-density lipoprotein cholesterol remains central in reducing cardiovascular
risk; however, the recent trials support a target of less than 2.0 mmol/l (< 80 mg/dl), rather than …

Objective To gain insight into the current management of patients with type 2 diabetes mellitus
by Canadian primary care physicians. Method A total of 479 primary care physicians from …

This guideline synthesizes clinical trial data supporting the role of glucagon-like peptide-1
receptor agonists and sodium-glucose co-transporter 2 inhibitors (SGLT2i) for treatment of …

Aim To conduct an adjusted indirect treatment comparison (aITC) of the efficacy of tirzepatide
5/10/15 mg versus semaglutide 2 mg in patients with type 2 diabetes. Materials and …

Aim To assess composite endpoints combining glycaemic control (HbA1c < 7.0%, ≤ 6.5%
or < 5.7%) with weight loss (≥ 5%, ≥ 10% or ≥ 15%) and without hypoglycaemia with …

Rates of diabetes are increasing in Canada, 1 and family physicians remain the main point
of primary care for people with diabetes. 2 The challenge for physicians in this context is to …

This guideline is directed to primary health care providers caring for Canadian adults who
have or are at risk of developing chronic cardiovascular diseases, including hypertension, …

Organizations around the world produce clin-ical practice guidelines at an astonishing pace,
with great effort and at substantial cost. 1 Unfortunately, despite broad dissemination efforts, …